Since their discovery, therapeutic or prophylactic vaccines represent a promising option to prevent or cure infections and other pathologies, such as cancer or autoimmune disorders. More recently, among a number of nanomaterials, gold nanoparticles (AuNPs) have emerged as novel tools for vaccine developments, thanks to their inherent ability to tune and upregulate immune response. Moreover, owing to their features, AuNPs can exert optimal actions both as delivery systems and as adjuvants. Notwithstanding the potential huge impact in vaccinology, some challenges remain before AuNPs in vaccine formulations can be translated into the clinic. The current review provides an updated overview of the most recent and effective application of gold nanoparticles as efficient means to develop a new generation of vaccine.

Gold nanoparticle-based platforms for vaccine development / R.M. Ferrando, L. Lay, L. Polito. - In: DRUG DISCOVERY TODAY: TECHNOLOGIES. - ISSN 1740-6749. - 38:(2020 Dec), pp. 57-67. [10.1016/j.ddtec.2021.02.001]

Gold nanoparticle-based platforms for vaccine development

L. Lay
Penultimo
;
2020

Abstract

Since their discovery, therapeutic or prophylactic vaccines represent a promising option to prevent or cure infections and other pathologies, such as cancer or autoimmune disorders. More recently, among a number of nanomaterials, gold nanoparticles (AuNPs) have emerged as novel tools for vaccine developments, thanks to their inherent ability to tune and upregulate immune response. Moreover, owing to their features, AuNPs can exert optimal actions both as delivery systems and as adjuvants. Notwithstanding the potential huge impact in vaccinology, some challenges remain before AuNPs in vaccine formulations can be translated into the clinic. The current review provides an updated overview of the most recent and effective application of gold nanoparticles as efficient means to develop a new generation of vaccine.
Settore CHIM/06 - Chimica Organica
   Glyco-Nanoparticles for Applications in Advance Nanomedicine (NanoCarb)
   NanoCarb
   EUROPEAN COMMISSION
   H2020
   814236
dic-2020
26-feb-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
DrugDiscoveryToday_2021_in press.pdf

accesso aperto

Descrizione: Online first
Tipologia: Publisher's version/PDF
Dimensione 726.61 kB
Formato Adobe PDF
726.61 kB Adobe PDF Visualizza/Apri
1-s2.0-S1740674921000032-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 821.82 kB
Formato Adobe PDF
821.82 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/828135
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 33
  • ???jsp.display-item.citation.isi??? ND
social impact